5 results about "Mesenchymal Progenitor Cell" patented technology

Provided herein are methods and related compositions for enhancing or enhanced partial reprogramming of target cells in a subject in need thereof (e.g., a human subject suffering from or at risk of a disease), the method comprising administering a plurality of mesenchymal lineage progenitor or stem cells (MLPSCs), exosomes derived therefrom, or conditioned culture media derived therefrom to a subject that expresses or will express one or more reprogramming factors in a population of target cells, whereby a plurality of the target cells in the subject become partially reprogrammed, but not fully reprogrammed.

Disclosed are methods of in situ genomic modification of cells (e.g., stem cells, tissue stem cells, muscle stem cells, Sca-1+ mesenchymal progenitor cells in skeletal muscle, CD140a+ dermal mesenchymal cells) using sequence-targeting nucleases delivered via a virus (e.g., an AAV).

Described herein are neonatal cardiac mesenchymal progenitor cells, an nMPC secretome, or an nMPC exosome for treating Amyotrophic Lateral Sclerosis (ALS) in a subject. One or more doses of neonatal cardiac mesenchymal progenitor cells, an nMPC secretome, an nMPC exosome, an nMPC total secretome, or a combination thereof can be administered to the subject. Neonatal cardiac mesenchymal progenitor cells can be allogeneic. The subject may also be administered one or more combination therapies.

The present disclosure relates to potency assays for cell therapy products. To provide a potency assay of a cell population comprising mesenchymal progenitor or stem cells.SOLUTION: The present invention relates to a method of measuring the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor or stem cells based on the levels of TGF-9 they release during culture. The invention also relates to an isolated population of mesenchymal lineage precursor or stem cells selected on the basis of the level of TGF-9 levels that the cells release in culture. The invention further relates to treating a subject suffering from degenerative disc disease by administering a cell population so selected.SELECTED DRAWING: None

To develop a ready-to-use ex vivo expanded allogeneic mesenchymal progenitor or stem cell (MLPSC) product having improved immunosuppressive activity.SOLUTION: The present disclosure relates to cell therapy products comprising mesenchymal lineage precursor or stem cells and potency assays for these products. The present disclosure also relates to a method for treating an immune or inflammatory disease, for treating or preventing graft versus host disease (GVHD) or one or more symptoms associated with GVHD by administering mesenchymal lineage precursor or stem cells.SELECTED DRAWING: None